

<b>Form PTO-1449</b> U.S. Department of Commerce Patent & Trademark Office  <b>INFORMATION DISCLOSURE STATEMENT</b> <i>(Use several sheets if necessary)</i>		<b>Atty. Docket No.</b> 147/49991	<b>Serial No.</b> TBA
		<b>Applicants</b> Johannes HEBE BRAND, et al.	
		<b>Filing Date</b> Herewith	<b>Group</b> 1655

  

U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Sub-Class	Filing Date (if appropriate)
	AA						

  

FOREIGN PATENT DOCUMENTS							
		Document	Date	Country	Class	Sub-class	Translation Yes   No
126	AB	EP0138441	04/1985	Europe			Yes
120	AC	WO9800130	01/1998	WO			Yes

  

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
126	AD	Karl M. WILBUR, "Electrometric and Colorimetric Determination of Carbonic Anhydrase" Journal of Biological Chemistry, Vol. 176, 1948
	AE	Claudia T. SUPURAN, "Carbonic anhydrase inhibitors and their therapeutic potential" Ashley Publications Ltd., pp. 1354-3776, 2000
	AF	MK HELLERSTEIN, "De novo lipogenesis in humans: metabolic and regulatory aspects" European Journal of Clinical Nutrition, 1993
	AG	Bruce E. MARYANOFF, "Structure-Activity Studies on Anticonvulsant Sugar Sulfamates Related to Topiramate. Enhanced Potency with Cyclic Sulfate Derivatives" J. Med. Chemistry, Vol. 41, pp. 1315-1343, 1998
	AH	Susanna J. DODGSON, "Topiramate as an Inhibitor of Carbonic Anhydrase Isoenzymes" Epilepsia, Vol. 41, 2000
	AI	Y. Pocker, J.T. STONE, "The Catalytic Versatility of Erythrocyte Carbonic Anhydrase. The Enzyme-Catalyzed Hydrolysis of p-Nitrophenyl Acetate" Journal of the American Chemistry Society, 87:23, 1965
	AJ	Robert W. HECK, "Catalytic Properties of Mouse Carbonic Anhydrase V*" The Journal of Biological Chemistry, Vol. 269, No. 40, 1994

  

<b>EXAMINER</b> 126 Gitomen	<b>DATE CONSIDERED</b> 8/11/05
-----------------------------	--------------------------------

  

<b>EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.
---



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	09/907,440	
Sheet	1	of	1	Filing Date	July 18, 2001
			First Named Inventor	JOHANNES HEBEBRAND	
			Art Unit	1851/655	
			Examiner Name	R J GITOMER	
			Attorney Docket Number	147/49991	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Country Code <sup>2</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)					
RG	AA	WO-94/09813-A1		05-11-1994	GENENTECH, INC.		

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

Examiner Signature	RGITOMER	Date Considered	8/11/05
-----------------------	----------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

FORM PTO-1449 U.S. Department of Commerce Patent & Trademark Office	Attorney Docket No. 147/49991	Serial No. 09/907,440
	Applicant: Johannes HEBEBRAND, et al.	
	Filing Date July 18, 2001	Group 1655

**INFORMATION DISCLOSURE STATEMENT**  
(Use several sheets if necessary)

U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Sub-Class	Filing Date (if appropriate)
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						

FOREIGN PATENT DOCUMENTS								
Examiner Initial		Document Number	Date	Name	Class	Sub-Class	TRANSLATION	
							Yes	No
	AK							
	AL							
	AM							
	AN							
	AO							
	AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)										
RG	AQ	Claudiu T. SUPURAN, et al., "Carbonic anhydrase inhibitors and their therapeutic potential" Expert Opinion on Therapeutic Patents, 2000								
RG	AR	M. K. HELLERSTEIN, et al., "De novo lipogenesis in humans: metabolic and regulatory aspects" European Journal of Clinical Nutrition, 1999								
	AS									

EXAMINER	RG 610MER	DATE CONSIDERED	8/11/05
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.			

Form PTO-1449		U.S. Department of Commerce Patent & Trademark Office	Atty. Docket No. 147/49991	Serial No. TBA
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			Applicants Johannes BEBE BRAND, et al.	
			Filing Date Herewith	Group 1655
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
126	AK	Gautam SANYAL, "Thermodynamics of Carbonic Anhydrase Catalysis" The Journal of Biological Chemistry, Vol. 256, No. 2, 1981		
	AL	James E. P. TOMAN, "Properties of Maximal Seizures, and their Alteration by Anticonvulsant Drugs and other Agents" University of Utah School of Medicine, 1946		
	AM	Y. POCKER, "The Catalytic Versatility of Erythrocyte Carbonic Anhydrase III. Kinetic Studies of the Enzyme-Catalyzed Hydrolysis of p-Nitrophenyl Actate" Biochemistry, Vol. 6, No. 3, 1967		
	AN	Claudia T. SUPURAN, "Carbonic anhydrase inhibitors-Part 53. Synthesis of substituted-pyridinium derivatives of aromatic sulfonamides: The first non-polymeric membrane-impermeable inhibitors with selectivity for isozyme IV" Eur. J. Med. Chemistry, Vol. 33, 1998		
	AO	Graham CHEN, "Evaluation of Five Methods for Testing Anticonvulsant Activities" Department of Pharmacology, Parke, Davis & Co., 1954		
	AP	Andrea SCOZZAFAVA, "Carbonic Anhydrase Inhibitors: Synthesis of Water-Soluble, Aminoacyl/Dipeptidyl Sulfonamides Possessing Long-Lasting Intraocular Pressure-Lowering Properties via the Topical Route" J. Med. Chemistry, Vol. 42, 1992		
	AQ	Raja G. KHALIFAH, "The Carbon Dioxide Hydration Activity of Carbonic Anhydrase" The Journal of Biological Chemistry, Vol. 246, No. 8, 1971		
	AR	Stacy A. HAZEN, "Differentiation-dependent expression of CA V and the role of carbonic anhydrase isozymes in pyruvate carboxylation in adipocytes" The FASEB Journal, 1995		
✓	AS	Bruce E. MARYANOFF, "Anticonvulsant O-Alkyl Sulfamates. 2,3:4,5-Bis-O-(1-methylethylidene)-B-D-fructopyranose Sulfamate and Related Compounds" American Chemistry Society, 1987		
EXAMINER		12 GIDMER	DATE CONSIDERED 8/11/05	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.				